Department of Ophthalmology, Başakşehir Çam and Sakura City Hospital, Turkey.
Department of Cardiology, Başakşehir Çam and Sakura City Hospital, Turkey.
Indian J Ophthalmol. 2024 Aug 1;72(8):1142-1146. doi: 10.4103/IJO.IJO_3201_23. Epub 2024 Jul 29.
It was aimed to compare corneal endothelial changes during the initial 12-month period in which patients started using atorvastatin after a diagnosis of acute coronary syndrome (ACS).
Forty-six participants (group 1) who underwent cardiac angioplasty and stenting for ACS and started using 80 mg atorvastatin in the early period were included in the study. In the study, a control group comprising 71 healthy adults (group 2) was included. These individuals did not use medication for any known systemic disease, had never taken statins, had no history of ocular surgery, and did not have any cornea-related eye diseases. Baseline and 12th month endothelial evaluations of group 1 and 2 participants were compared using specular microscopy.
There were 28 female and 18 male participants in group 1 and 48 female and 23 male participants in group 2 (P = 0.455). The mean baseline corneal endothelial cell density (CECD) was not significantly higher in group 1 compared to group 2 (2471.4 ± 200 cells/mm2 vs 2428.2 ± 539.8 cells/mm2, P = 0.230). When the change between baseline and 12th month CECD was examined, the decrease in group 2 was significantly different from that in group 1 (-15,2 ± 31,9 and -44,8 ± 49,6, P = 0,002). Although the percentage of hexagonal cells decreased significantly in group 2 participants, no significant change was observed in group 1 (respectively; P < 0.001, P = 0.073). The endothelial cell coefficient of variation did not differ significantly in group 1 participants over a 1-year period (P = 0.192), and a significant increase was observed in group 2 (P < 0.001).
This study revealed that atorvastatin may have a positive effect on corneal endothelium cell density and morphology.
旨在比较急性冠脉综合征（ACS）患者诊断后开始使用阿托伐他汀最初 12 个月期间的角膜内皮变化。
本研究纳入了 46 名接受心脏血管成形术和支架置入术治疗 ACS 并在早期开始使用 80mg 阿托伐他汀的患者（第 1 组）。研究纳入了 71 名健康成年人作为对照组（第 2 组）。这些个体没有使用任何已知系统性疾病的药物，从未服用过他汀类药物，没有眼部手术史，也没有任何与角膜相关的眼部疾病。使用共焦显微镜比较第 1 组和第 2 组参与者的基线和第 12 个月的内皮评估。
第 1 组有 28 名女性和 18 名男性，第 2 组有 48 名女性和 23 名男性（P=0.455）。第 1 组的角膜内皮细胞密度（CECD）基线值与第 2 组相比没有显著升高（2471.4±200 个细胞/mm2与 2428.2±539.8 个细胞/mm2，P=0.230）。当比较基线和第 12 个月 CECD 的变化时，第 2 组的下降与第 1 组有显著差异（-15.2±31.9 和-44.8±49.6，P=0.002）。尽管第 2 组参与者的六边形细胞百分比显著下降，但第 1 组没有观察到显著变化（分别为；P<0.001，P=0.073）。第 1 组参与者在 1 年内内皮细胞变异系数没有显著差异（P=0.192），而第 2 组则显著增加（P<0.001）。
本研究表明，阿托伐他汀可能对角膜内皮细胞密度和形态有积极影响。
